Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934351 | 0.86 | CCR6 (0.41) | GSK3B | |
| SCHEMBL4284032 | 0.85 | GSK3B (0.49) | GSK3B | |
| Hydrochloric Acid SCHEMBL4281663 | 0.85 | CCR6 (0.41) | GSK3B | |
| SCHEMBL2932471 | 0.85 | IL1B (0.33) | GSK3BCNR1IL1B | |
| Hydrochloric Acid SCHEMBL4281341 | 0.84 | IL1B (0.32) | GSK3BIL1B | |
| SCHEMBL1918776 | 0.74 | GSK3B (0.49) | GSK3BCNR1CNR2IL1B | |
| SCHEMBL2926625 | 0.73 | CNR1 (0.33) | GSK3BCNR1CNR2 | |
| SCHEMBL2930956 | 0.68 | GSK3B (0.43) | GSK3BCNR1CNR2IL1B | |
| SCHEMBL4287388 | 0.68 | GSK3B (0.51) | GSK3BCNR1CNR2IL1B | |
| SCHEMBL17012104 | 0.66 | GSK3B (0.41) | GSK3BCNR1CNR2IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | GSK3B 2707/4885CNR1 2270/4885CNR2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.